Which patient groups require monitoring for thrombotic complications when receiving albutrepenonacog alfa (Idelvion)?

Patients receiving albutrepenonacog alfa (Idelvion) who have liver disease, are postoperative, are newborn infants, or are at risk of thrombosis or disseminated intravascular coagulation require clinical surveillance and appropriate biological testing for early thrombotic and consumptive coagulopathy signs.